

The FDA approved Roche’s oral breast cancer drug Wilserdly and kidney disease therapy Gazyva following positive Phase 3 clinical trial data.
You can purchase shares of ROCHE HOLDING LTD S/ADR by Roche Holding Ltd (OTCQX:RHHBY) through any online brokerage.
There are no as such competitors for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd.
There is no analysis for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd to provide a consensus price target.
The stock price for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd (OTCQX: RHHBY) is $60.37 last updated November 17, 2026 at 8:58 AM EST.
There are no upcoming dividends for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd.
ROCHE HOLDING LTD S/ADR by Roche Holding Ltd does not have any upcoming earnings scheduled.
There is no upcoming split for ROCHE HOLDING LTD S/ADR by Roche Holding Ltd.
ROCHE HOLDING LTD S/ADR by Roche Holding Ltd is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCQX.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana...